Director, CEO · Editas Medicine, Inc. · Common Stock
Side
A
Value
—
Shares
43.6K
Price
—
Executed
Nov 5, 2026
Disclosed
Nov 6, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Nov 5 executedNov 6, 2026 disclosed
EDIT · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 17.9% of prior position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
O'Neill Gilmore Neil filed this Form 4 reporting a grant or award of EDIT on Nov 5, 2026. It became public on Nov 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, CEO
O'Neill Gilmore Neilcik:0001742084
Issuer
Editas Medicine, Inc.cik:0001650664
Revision history · 0
No field has changed since this record was first ingested.
